海正药业：子公司获得甲泼尼龙片（犬用）新兽药注册证书

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Animal Health, has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic positioning in the veterinary medicine sector [2]. Group 1 - The product, Methylprednisolone Tablets (for dogs), is intended for the treatment of canine inflammatory and allergic diseases [2]. - The approval was granted by the Ministry of Agriculture and Rural Affairs, indicating that the product meets relevant regulatory standards [2]. - The development of this product was a collaborative effort among Haizheng Animal Health and six other companies [2]. Group 2 - The new veterinary drug registration certificate signifies that the product is ready for production and market launch [2]. - Despite the approval, it is noted that there will be no significant short-term impact on the company's financial performance [2]. - This development is expected to enhance the company's competitiveness in the veterinary medicine market [2].